OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) will present fourth quarter and
year end Tarceva® (erlotinib) sales today during the
Company’s presentation at the 28th Annual JP Morgan
Healthcare Conference in San Francisco, CA. For the three months ended
December 31, 2009, Tarceva U.S. net sales, as communicated to the
Company by its collaborator Roche, were approximately $137 million. U.S.
sales increased approximately $20 million (or 17%) over the same period
last year and were up approximately $19 million over third quarter sales
of approximately $118 million. Fourth quarter net sales outside the U.S.
were approximately $196 million, also representing a 17% increase over
the same period last year and an increase of approximately $13 million
over third quarter sales.
Total worldwide net sales of Tarceva for 2009, were approximately $1.2
billion, representing a 7% growth in global sales compared to 2008. Full
year net sales of Tarceva in the U.S. totaled approximately $479 million
with full year net sales outside of the U.S. totaling approximately $724
million. The Company expects to present full fourth quarter and year end
financial results in its year end earnings call.
About OSI Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicine and changing
lives" by discovering, developing and commercializing high-quality,
novel and differentiated targeted medicines designed to extend life and
improve the quality of life for patients with cancer and
diabetes/obesity. For additional information about OSI, please visit http://www.osip.com.
This news release contains forward-looking statements. These
statements are subject to known and unknown risks and uncertainties that
may cause actual future experience and results to differ materially from
the statements made.
Factors that might cause such a difference
include, among others, OSI's and its collaborators' abilities to
effectively market and sell Tarceva and to expand the approved
indications for Tarceva, OSI’s ability to protect its intellectual
property rights, safety concerns regarding Tarceva,
competition
to Tarceva and OSI’s drug candidates
from other biotechnology and
pharmaceutical companies, the completion of clinical trials, the
effects of FDA and other governmental regulation, including pricing
controls,
OSI's ability to successfully develop and commercialize
drug candidates, and other factors described in OSI Pharmaceuticals'
filings with the Securities and Exchange Commission.
